Financing (Narrative) (Details) € in Millions, SFr in Billions			9 Months Ended
	Oct. 10, 2025 USD ($)	Oct. 10, 2025 CHF (SFr)	Sep. 26, 2025 EUR (€)	Sep. 26, 2025 USD ($)	Sep. 15, 2025 USD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
Debt discounts, premiums and debt issuance costs				$ 88,000,000			$ 96,000,000
Long-term debt				16,833,000,000			15,500,000,000
Borrowings outstanding				16,856,000,000			16,005,000,000
Subsequent event
Debt Instrument [Line Items]
Proceeds from debt, net	$ 1,600,000,000	SFr 1.2
Multi-year Credit Facility | Revolving credit facility | Line of credit
Debt Instrument [Line Items]
Line of credit facility				5,000,000,000
Euro Denominated Commercial Paper and 2026 Biopharma Euro Notes
Debt Instrument [Line Items]
Long-term debt				$ 2,600,000,000
Euro-denominated commercial paper | Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate of long-term debt, interest rate			2.20%	2.20%
Weighted average maturity of long-term debt, at point in time			27 days
Borrowings outstanding			€ 933	$ 1,092,000,000		€ 931	965,000,000
U.S. dollar-denominated commercial paper | Commercial paper
Debt Instrument [Line Items]
Borrowings outstanding				0
3.35% senior notes due 2025 | Senior notes
Debt Instrument [Line Items]
Borrowings outstanding				0			500,000,000
Aggregate principal amount				$ 500,000,000	$ 500,000,000		$ 500,000,000